Carol Aghajanian

Carol Aghajanian, MD, is a leading gynecologic medical oncologist at Memorial Sloan Kettering Cancer Center, specializing in the treatment of cervical, fallopian tube, uterine, and ovarian cancers. She serves as Chief of the Gynecologic Medical Oncology Service and holds the prestigious Avon Chair in Gynecologic Oncology Research, driving innovative chemotherapy protocols for ovarian cancer treatment.

• MD from SUNY Health Science Center at Brooklyn
• Completed Internal Medicine residency at Mount Sinai Hospital
• Fellowship in Medical Oncology/Hematology at Memorial Sloan Kettering

Her research focuses on chemotherapy optimization, genetic testing mainstreaming, and targeted therapies for gynecologic cancers. She leads MSK's participation in the Gynecologic Oncology Group (GOG) and chairs the Phase I and Medical Oncology Committees, emphasizing clinical trial development for germ cell tumors and gestational trophoblastic disease.

Analysis of her recent publications reveals expertise in ovarian cancer genomics, immunotherapy combinations, and MEK/FAK inhibition. Key trends include her work on germline variants, TROP2 targeting in carcinosarcoma, and chemotherapy-immunotherapy integration for poor-prognosis cancers.

Scientific Awards & Recognition:

• Boyer Award for outstanding young investigators (MSK)
• Castle Connolly America's Top Doctor (2023-2025)
• Exceptional Women in Medicine Award (2023-2024)
• New York Magazine Top Doctors (2015-2020)

As a co-principal investigator for multiple clinical trials, Dr. Aghajanian has shaped treatment paradigms through NRG Oncology and GOG collaborations. Her work specifically addresses drug resistance mechanisms, genomic instability scores, and personalized approaches for recurrent gynecologic cancers.